This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In an unusual move, an audit of commercial health plans by Tennessee officials found that Express Scripts, one of the largest pharmacy benefit managers in the United States, violated state laws in its dealings with pharmacies, according to newly released documents. A department spokesperson declined to comment.
Last week, we documented the substantial concentration of dispensing revenues for specialty drugs. See The Top 15 SpecialtyPharmacies of 2023: Market Shares and Revenues at the Biggest PBMs, Health Plans, and Independents. Today, we examine how manufacturers’ specialty networks contribute to this concentration.
Last week, we documented the substantial concentration of dispensing revenues for specialty drugs. See The Top 15 SpecialtyPharmacies of 2023: Market Shares and Revenues at the Biggest PBMs, Health Plans, and Independents. Today, we examine how manufacturers’ specialty networks contribute to this concentration.
340B ESP and drug manufacturer restrictions are only part of the reason As we noted in a previous post , for 340B-eligible hospitals dealing with increasingly squeezed bottom lines, an in-house specialtypharmacy offers enormous savings and revenue potential. Hospitals can operate specialtypharmacies alongside their retail pharmacies.
Why a SpecialtyPharmacy? Overview) As chronic illnesses become increasingly common in the United States, the number of specialty medications for managing these conditions has skyrocketed. Which is why, according to some online reports, nearly 80% of new drug introductions are now specialty medications. Better Incomes.
Why a SpecialtyPharmacy? Overview) As chronic illnesses become increasingly common in the United States, the number of specialty medications for managing these conditions has skyrocketed. Which is why, according to some online reports, nearly 80% of new drug introductions are now specialty medications. Better Incomes.
Why a SpecialtyPharmacy? Overview) As chronic illnesses become increasingly common in the United States, the number of specialty medications for managing these conditions has skyrocketed. Which is why, according to some online reports, nearly 80% of new drug introductions are now specialty medications. Better Incomes.
Between late 2019 and the end of 2023, ProxsysRx’s 340B Support program went from Zero to more than $500 million in savings generated for the hospitals and health systems we serve. Understand, and master, your 340B specialtypharmacy opportunities. The 340B revenue potential of specialtypharmacy is staggering.
The discussion focused on CMS’ 2023 listening sessions during implementation of the first round of negotiations and identified lessons learned to inform future listening sessions and broader patient engagement strategies. Pharmacy benefit managers: transparency, accountability, and impact on patient care. Casalino, L., and Richman, B.
Study Overview Researchers conducted a retrospective chart review of 80 patients aged 12 or older within Intermountain Health who were diagnosed with asthma between December 2022 and December 2023. 1 The study also observed that 65% of patients had a documented visit with an asthma specialist during the follow-up period.
I am pleased to announce our new 2023–24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. The notable new material in this 2023-24 edition includes: New data about commercial pricing and reimbursement for provider-administered biosimilars appears in Section 3.2.2.
If a discrepancy is found, the pharmacy nurses will hold the shipment, and a clinical intervention will be communicated to the provider. Results American Oncology Network (AON) Pharmacy collected data on waste and cost avoidance from February 2023 to September 2023. Withholding shipment saved $1.9
According to the Centers for Disease Control and Prevention (CDC), as of 2023, 27 percent of U.S. 15 The NHC advocates for rigorous, transparent documentation of the medical rationale in such instances to prevent discriminatory practices. adults have a disability that impacts major life activities.13 Section 84.4(e) 6 Gopal, D.,
The evolving legal and legislative landscape surrounding the 340B Drug Pricing Program has significant implications for hospitals’ specialtypharmacies. Here’s a breakdown of the new developments and their likely impacts: Recent 340B changes and their impact on specialtypharmacies 1.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content